

Physiological and Biophysical Factors that Influence Alzheimer's Disease Amyloid Plaque Targeting of Native and Putrescine Modified Human Amyloid β 40

Karunya K. Kandimalla*, Geoffry L. Curran, Silvina S. Holasek, Emily J. Gilles,
Thomas M. Wengenack, Marina Ramirez-Alvarado, and Joseph F. Poduslo

Molecular Neurobiology Laboratory

Departments of Neurology, Neuroscience, and Biochemistry/Molecular Biology (*KK, GC, SH, EG, TW, JP*), Department of Biochemistry/Molecular Biology (MRA)

Mayo Clinic College of Medicine, Rochester, MN 55905

Running title: Amyloid plaque targeting of AB40 in Alzheimer's disease

Corresponding author: Joseph F. Poduslo

Address: Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN55905

Phone: (507) 284 1784

Fax: (507) 284 3383

Email: poduslo.joseph@mayo.edu

Number of text pages: 22

Number of tables: 1

Number of figures: 10

Number of references: 22

Number of words in the abstract: 248

Number of words in the introduction: 620

Number of words in the discussion: 1393

Abbreviations:

AD, Alzheimer's disease; A β 40, unlabeled amyloid beta 40; 125 I-A β 40, amyloid beta 40 labeled with 125 I; APP, amyloid precursor protein; PS1, presenilin 1; WT, wild type; BBB, blood brain barrier; CSF, cerebrospinal fluid; IV, intravenous; BSA, bovine serum albumin; BCA, Bicinchoninic acid protein assay reagent ; TCA, trichloroacetic acid; V_p , residual brain region plasma volume; PS, cerebrovascular permeability coefficient-surface area product ; KRB, Kreb's Ringer bicarbonate buffer; DMEM, Dulbecco's modified eagle medium; 2,4-DNP, 2,4-dinitrophenol; V_{ss} , steady state volume of distribution; AUC, area under the plasma concentration curve; Cl, clearance.

Section option: Absorption, Distribution, Metabolism & Excretion

ABSTRACT

Amyloid β 40 ($A\beta$ 40) and its derivatives are being developed as probes for the ante-mortem diagnosis of Alzheimer's disease (AD). Putrescine- $A\beta$ 40 (PUT- $A\beta$ 40) showed better plaque targeting than the native $A\beta$ 40, which was not solely explained by the differences in their blood-brain-barrier (BBB) permeabilities. The objective of this study was to elucidate the physiological and biophysical factors influencing the differential targeting of $A\beta$ 40 and PUT- $A\beta$ 40. Despite better plaque targeting ability, ^{125}I -PUT- $A\beta$ 40 was more rapidly cleared from the systemic circulation than ^{125}I - $A\beta$ 40 following IV administration in mice. The BBB permeability of both compounds was inhibited by circulating peripheral $A\beta$ 40 levels. ^{125}I - $A\beta$ 40 but not ^{125}I -PUT- $A\beta$ 40 was actively taken up by the mouse brain slices in-vitro. Only Fluorescein- $A\beta$ 40 and not Fluorescein-PUT- $A\beta$ 40 was localized in the brain parenchymal cells in-vitro. The metabolism of ^{125}I - $A\beta$ 40 in the brain slices was twice as great as ^{125}I -PUT- $A\beta$ 40. ^{125}I - $A\beta$ 40 efflux from the brain slices was saturable and found to be five times greater than that of ^{125}I -PUT- $A\beta$ 40. Thioflavin-T fibrillogenesis assay demonstrated that PUT- $A\beta$ 40 has a greater propensity to form insoluble fibrils compared to $A\beta$ 40, most likely due to the ability of PUT- $A\beta$ 40 to form β sheet structure more readily than $A\beta$ 40. These results demonstrate that the inadequate plaque targeting of $A\beta$ 40 is due to cellular uptake, metabolism, and efflux from the brain parenchyma. Despite better plaque targeting of PUT- $A\beta$ 40, its propensity to form fibrils may render it less suitable for human use and thus allow increased focus on the development of novel derivatives of $A\beta$ with improved characteristics.

INTRODUCTION

Amyloid β ($A\beta$) protein is a hydrophobic peptide that is thought to be neurotoxic. A consensus is emerging that $A\beta$ proteins, as soluble monomers or polymers, play a critical role in the neurotoxicity and subsequent development of amyloid plaque formation which contributes to the pathology of Alzheimer's disease (AD). The extracellular accumulation of $A\beta$ peptides into plaques is one of the pathological hallmarks for the definitive post-mortem diagnosis of AD. A diagnostic imaging technique capable of directly visualizing these amyloid plaques will provide not only a more definitive premortem diagnosis of AD, but also a tool for prognostication and evaluation of putative therapies (Poduslo et al., 2002).

Currently, no method exists to image "individual" amyloid plaques in humans for a definitive and early diagnosis of AD. Radiolabeled molecular probes that bind to β -amyloid plaques have recently been demonstrated both *in vitro* and in animal studies (Skovronsky et al., 2000; Wengenack et al., 2000a; Agdeppa et al., 2001; Bacskai et al., 2001). The most notable of these probes is the Pittsburgh compound-B, which allowed the researchers to visualize amyloid plaques by bulk tissue enhancement after PET imaging for the first time in AD patients (Klunk et al., 2004). While scintigraphic imaging of β -amyloid plaques is promising, certain difficulties may be envisioned for clinical application. The most obvious is poor spatial resolution. The spatial resolution of clinically available tomographic scintigraphic techniques (positron emission tomography or single-photon emission computed tomography) is several times poorer than that of standard 3D magnetic resonance imaging (MRI).

The ability of human A β 40 and PUT-A β 40 to selectively target amyloid plaques in AD transgenic mouse (APP,PS1) brain has provided an opportunity to use them as molecular probes to image amyloid plaques with MRI. ¹²⁵I-A β 40 was reported to have high in vitro binding affinity to the amyloid plaques in human and APP,PS1 mouse brain slices and high in vivo permeability at the BBB (Zlokovic et al., 1993; Maness et al., 1994; Poduslo et al., 1997; Poduslo et al., 1999; Mackic et al., 2002); however, the plaque targeting ability of ¹²⁵I-A β 40 following IV injection in AD transgenic mice was low (Wengenack et al., 2000a). The putrescine modified A β 40 (PUT-A β 40) was shown to have two fold higher BBB permeability than unmodified A β 40 and was able to target and label amyloid plaques in APP,PS1 animals following intravenous administration. When covalently linked to gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA), which provides contrast for MRI imaging, Gd-PUT-A β 40 was able to provide enough contrast to image amyloid plaques in APP,PS1 mice while Gd-A β 40 failed to provide the required contrast (Poduslo et al., 2002). The differences in the efficacy of these compounds to label plaques ex-vivo cannot be completely explained by the differences in their permeability values at the BBB.

Permeability at the blood-brain-barrier (BBB), endothelial transcytosis, as well as diffusion within and efflux from the brain parenchyma are important factors that determine the amount of A β -probe available to target plaques. The proportion of A β -probe in the extracellular space of the brain parenchyma versus intracellular uptake is another important consideration that will determine the successful targeting of amyloid plaques. Adequate knowledge of the transport kinetics of human A β protein and its

derivatives at the BBB and in the brain will allow us to design smart molecular probes capable of labeling plaques in Alzheimer's patients, as well as provide further information regarding the dynamics of A β transport in the progression of AD.

The objective of the current study is to investigate various factors affecting the 1) in vivo uptake of A β 40 and PUT- A β 40 at the BBB; 2) accumulation within and efflux from the brain tissue in vitro; and 3) binding to the amyloid plaques, as a means to explain the better targeting ability of PUT- A β 40 over native A β 40.

MATERIALS AND METHODS

Synthesis of human A β 40.

A β 40 was synthesized on an ABI 433 peptide synthesizer (Foster City, CA) using HBTU activation and the manufacturer's suggested synthesis protocols. The starting resin was Val-NovaSyn TGA resin (Calbiochem-Novabiochem, San Diego, CA). The peptides were cleaved from the solid support using 5% crystalline phenol, 5% water, 2.5% triisopropylsilane and 87.5% TFA for two hours at room temperature and were purified by reverse-phase HPLC using a heated 250 x 21.2 mm C18 Jupiter column (Phenomenex Corp). The weights of the peptides were confirmed by electrospray ionization mass spectrometry (Sciex API 165).

Synthesis of fluorescein labeled A β 40 (F-A β 40). After the final deprotection of the N-terminal Fmoc group, the peptide resin was washed with 12% diisopropylethylamine/dichloromethane (DIEA/DCM). A two equivalent excess of NHS-

fluorescein (Pierce, Rockford, IL) was dissolved in 6 ml of dimethylformamide (DMF) and added to the resin saturated with 12% DIEA/DCM. The resin slurry was mixed overnight at room temperature, followed by several washes with DMF and DCM. The success of the fluorescein addition was confirmed by a negative ninhydrin reaction.

Putrescine modification of A β 40 and F-A β 40. Putrescine modification of synthetic human A β 40 and F-A β 40 was performed by covalent linkage of the polyamine to carboxylic acid groups using carbodimide at pH of 6.7 as described previously (Poduslo and Curran, 1996a; Poduslo and Curran, 1996b)

Radioiodination of proteins. A 500 μ g of Human A β 40 or PUT- A β 40 was labeled with carrier-free Na¹²⁵I, whereas the bovine serum albumin (BSA) (500 μ g) was labeled with carrier-free Na¹³¹I using the chloramine-T procedure as described previously (Poduslo et al., 2001). Free radioactive iodine was separated from the radiolabeled protein by dialysis against 0.01 M phosphate buffered saline at pH 7.4 (Sigma-Aldrich Co., St. Louis, MO). Purity of the radiolabeled proteins was determined by trichloroacetic acid (TCA) precipitation. The radiolabeled protein was considered to be acceptable if the precipitable radioactive counts were greater than 95% of the total counts. The specific activity of the proteins thus obtained was determined as 2.0 ± 0.1 μ Ci/ μ g. No significant difference was observed between the specific activities of ¹²⁵I-A β 40 and ¹²⁵I-PUT-A β 40.

Animals. Wild type (WT mice (B6/SJL strain) were obtained from the Jackson Laboratory (Bar Harbor, ME). The mice were housed in a virus-free barrier facility under a 12-hr light/dark cycle, with ad libitum access to food and water. All the experimental procedures were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals using protocols approved by the Mayo Institutional Animal Care and Use Committee.

PUT-A β 40 pharmacokinetics studies. Before the beginning of the experiment, the femoral vein and the femoral artery of each mouse were catheterized under general anesthesia (Poduslo et al., 2001). An IV bolus dose of ^{125}I -PUT-A β 40 (100 μCi in 100 μl) was administered through the femoral vein. Blood samples (20 μl) were obtained from the femoral artery at 0.25, 1, 3, 5, 10 and 15 min intervals. At the end of the experiment, an IV bolus dose of ^{131}I -BSA (100 μCi in 100 μl) was administered to serve as a measure of residual plasma volume (V_p). One minute following the ^{131}I -BSA injection, the final blood sample was collected, and the animal was sacrificed. The blood samples were diluted to a volume of 100 μl using normal saline, centrifuged, and the supernatant was obtained. Following TCA precipitation, the supernatant was assayed for ^{125}I and ^{131}I radioactivity in a two-channel gamma counter (Cobra II, Packard). The measured activity was corrected for the background and crossover of ^{131}I activity into the ^{125}I channel. At the end of the experiment, the brain of the animal was removed from the cranial cavity, dissected into cortex, caudate putamen, hippocampus, thalamus, brain stem, and cerebellum, and assayed for ^{125}I and ^{131}I radioactivity. The effect of A β 40 on the ^{125}I -PUT-A β 40 uptake at the blood brain barrier was determined by both

co-administering and sequential administration of 1 mg of unlabelled A β 40 with 100 μ Ci of 125 I-PUT-A β 40.

Metabolism of 125 I-PUT-A β 40. The metabolism of 125 I-PUT-A β 40 in the plasma of WT mice was determined by adding 0.1 μ Ci of 125 I-PUT-A β 40 to 350 μ l of plasma. A 20 μ l sample was taken from the mixture at regular intervals up to 60 min and the amount of intact 125 I-PUT-A β 40 in the sample was determined by TCA precipitation. The metabolism of 125 I-PUT-A β 40 in the presence of brain, liver, kidney and spleen slices was determined using the organs obtained from WT mice following perfusion with PBS. The organs were weighed, chopped into 1mm thick slices using a tissue slicer (Stoelting Co. Wood Dale, IL) and placed in oxygenated (95% O $_2$ and 5%CO $_2$) KRB until the start of the experiment. The tissue slices were then transferred to 5 ml of KRB containing 0.1 μ Ci of 125 I-PUT-A β 40 and incubated at 37°C under 5% CO $_2$ for the entire length of the experiment. Samples (20 μ l) of the medium were obtained at regular intervals and assayed for the intact protein by TCA precipitation.

Brain Slices. After sacrificing with an overdose of sodium pentobarbital (200 mg/kg, IP), the animals were decapitated and the brains were carefully removed from the cranial cavity. Each brain was cut coronally into 1 mm thick slices containing cortex and hippocampus. The slices were placed in oxygenated (95% O $_2$ and 5%CO $_2$) KRB until the start of the experiment.

Brain slice uptake of 125 I-A β 40 and 125 I-PUT-A β 40

Effect of time. Following the equilibration in KRB, each brain slice was incubated in 1 ml of donor solution containing ^{125}I - A β 40 (0.8 $\mu\text{Ci}/\text{ml}$ of KRB) at 37°C. The brain slices were sampled at different time points (0, 10, 15, 30, 45, and 60 min), rinsed with KRB, and assayed for ^{125}I radioactivity in a two-channel gamma counter (Cobra II, Packard).

Effect of donor concentration. Following the equilibration, each brain slice was incubated at 37°C in a 1 ml donor solution containing different concentrations of ^{125}I - A β 40 (0.05-28.4 $\mu\text{Ci}/\text{ml}$ of KRB). After 15 min, the brain slices were removed from the donor solutions, rinsed with KRB, and assayed for radioactivity using a dual channel gamma counter.

Effects of metabolic inhibitors. Following the equilibration, brain slices was pre-incubated with the metabolic inhibitors ouabain (1mM) or 2,4-dinitrophenol(2,4-DNP) (1mM) for 30 minutes. Each brain slice was then transferred to 1 ml donor solution (pre-incubate + 0.6 $\mu\text{Ci}/1\text{ ml}$ of ^{125}I -A β 40 or PUT-A β 40) maintained at 37°C. After 15 min, the brain slices were removed, rinsed with KRB, and assayed for radioactivity in a two-channel gamma counter.

Cellular accumulation of F-A β 40 and F-PUT-A β 40 in the brain parenchyma. Each brain slice was incubated in 1 ml of donor solution containing F-A β 40 or F-PUT-A β 40 (40 $\mu\text{g}/\text{ml}$ of KRB) at 37 °C. After 15 min, the slice was removed from the donor solution, placed on a cover slip moistened with KRB and imaged under a Zeiss LSM 410 (Carl Zeiss, Thornwood, NY) laser confocal microscope

^{125}I -A β 40 and ^{125}I -PUT-A β 40 efflux from brain slices.

WT mice brain slices were equilibrated in KRB for 15 min at 37°C. Each slice was then incubated in a 1 ml donor solution containing various concentrations of ¹²⁵I-Aβ40 or ¹²⁵I-PUT-Aβ40 at 37°C for 30 minutes, washed with KRB and incubated in 5 ml of KRB (receiving medium). The brain slices were harvested at various time points: 0, 10, 15 and 30 min, rinsed with KRB and assayed for ¹²⁵I radioactivity. The initial rates of efflux (<15 min) of these compounds from the brain slices were calculated at various donor concentrations. The rates of efflux were normalized by the donor concentrations and plotted against log donor concentrations.

Aβ40 and PUT-Aβ40 fibril formation. Thioflavin T (THT) is a fluorescent dye that exhibits substantial enhancement in the fluorescence intensity upon binding to amyloid fibrils. Due to an excellent correlation between the THT fluorescence and the amount of amyloid fibrils, THT fibrillogenesis assay is widely used to quantify the amyloid fibril formation. In the current study, Aβ40 and PUT-Aβ40 fibril formation kinetics were followed using THT fibrillogenesis assay, which is detailed as follows: Aβ40 and PUT-Aβ40 were incubated at 37°C in TRIS-EDTA buffer (50mM Tris, 5mM EDTA and 150 mM NaCl) under continuous shaking (200 rpm) for 24 hours. A 60 μl aliquot of the reaction mixture was obtained at 0, 1, 2, 4, 6, 9, 12, 24, 48, 90 and 120 hrs, mixed with 1.2 ml of 5 μM Thioflavin T (THT) in TRIS-EDTA and assayed for fluorescence (excitation λ = 450 nm and emission λ = 480 nm). The fluorescence intensity of each compound was normalized with the maximal fluorescence value of the compound and plotted against time.

Circular Dichroism (CD) Spectroscopy. The secondary structures of A β 40 and PUT-A β 40 were determined using CD spectroscopy. A 20 μ M solution of each protein was prepared in PBS (pH = 7.2), filtered using 0.22 μ m syringe filter, and transferred to a 0.2 cm path length quartz cuvette. The CD spectra of A β 40 and PUT-A β 40 were obtained from 260-200 nm at 4 °C, scanning every 1 nm with an averaging time of 5 sec, on an AVIV CD spectrometer Model 215 (AVIV Instruments).

Data Analysis. The 125 I-PUT-A β 40 plasma concentration profile following the single intravenous bolus dose of 125 I-A β 40 was best described by a biexponential disposition function $C(t) = Ae^{-\alpha t} + Be^{-\beta t}$, where $C(t) = ^{125}$ I-PUT-A β 40 / ml of plasma, A and B are the intercepts and α and β are the slopes of the biexponential curve. Pharmacokinetic parameters were estimated by nonlinear curve fitting using Gauss-Newton (Levenberg and Hartley) algorithm and iterative reweighting (WinNonlin[®] Professional, version 4.1, Mountain view, CA). Secondary parameters such as the C_{\max} (maximum plasma concentration), the first ($t_{1/2(\alpha)}$) and the second ($t_{1/2(\beta)}$) phase half-lives, the plasma clearance (Cl), the steady-state volume of distribution (V_{ss}), and area under the plasma concentration curve (AUC) were also calculated using WinNonlin. The mean values of controls and treatments were compared by Student's t-test using GraphPad Prism version 4.0 (GraphPad Software, San Diego California USA).

PS and V_p measurements were calculated as described previously by Poduslo (1993). The residual brain region plasma volume (V_p , μ l/g) is calculated as

$$V_p = \frac{q_p \times 10^3}{C_v \times WR}, \quad \text{Eqn. 1}$$

where q_p is the radioactivity (cpm) of ^{131}I -BSA present in the tissue. C_v is the ^{131}I -BSA concentration (cpm/ml) in plasma, W is the dry weight (g) of the brain region, and R is the wet weight / dry weight ratio for mice of a defined age group. From the total ^{125}I -A β 40 content (q_T) (cpm) of the brain region, the amount of ^{125}I -A β 40 that enters the brain region extravascular space (q) (cpm/g) is calculated as

$$q = \frac{q_T}{WR} - \frac{V_p C_a}{10^3}, \quad \text{Eqn. 2}$$

where C_a is the final ^{125}I -A β 40 concentration (cpm/ml) in plasma. The PS (ml/g/s) of the BBB is calculated as

$$PS = \frac{q(t)}{\int_0^t C_p dt}, \quad \text{Eqn. 3}$$

where t is the circulation time, $q(t)$ is the extravascular ^{125}I activity in the brain region at

time t , and $\int_0^t C_p dt$ is the plasma concentration time integral of ^{125}I -A β 40.

The initial rates of efflux of ^{125}I -A β 40 and ^{125}I -PUT-A β 40 from the WT brain slices were normalized by the donor concentrations and plotted against log donor concentrations (log C). The inhibitory concentrations (IC_{50}) of ^{125}I -A β 40 efflux from the brain slices in vitro was determined by fitting the following equation to the data using GraphPad Prism version 3.03 (GraphPad Software, San Diego, CA).

$$NE = NE_{\min} + \frac{(NE_{\max} - NE_{\min})}{1 + 10^{(\log C - \log \text{IC}_{50})}} \quad \text{Eqn. 4}$$

where NE_{max} is the maximum normalized efflux value, which was obtained at the lowest ^{125}I -A β 40 concentration. NE_{min} is the minimum NE value obtained at the highest ^{125}I -A β 40 concentration.

RESULTS

The in vivo targeting abilities of molecular probes may be compromised due to: 1) rapid elimination from the systemic circulation; 2) competitive inhibition by high circulating A β levels in APP,PS1 mice; 3) proteolytic degradation in the brain parenchyma; 4) uptake and degradation by neurons; and 5) efflux from the brain. In this study, we systematically studied and compared the influence of each of the above factors on the amyloid plaque targeting of A β 40 and PUT-A β 40.

^{125}I -PUT-A β 40 plasma pharmacokinetics. Upon IV administration, the ^{125}I -PUT-A β 40 concentrations in the plasma of WT mice declined rapidly exhibiting a bi-exponential disposition with short α and β half-lives ($t_{1/2(\alpha)}$ and $t_{1/2(\beta)}$, respectively) (Figure 1, Table 1). The C_{max} , $t_{1/2(\alpha)}$ and AUC were significantly lower, whereas the clearance (Cl) and steady state volume of distribution (V_{ss}) was significantly higher for ^{125}I -PUT-A β 40 compared to previously reported values for ^{125}I -A β 40 (Kandimalla et al., 2005). These differences are mostly likely due to rapid clearance normally observed for cationized proteins (Dellian et al., 2000) or significantly higher metabolism of ^{125}I -PUT-A β 40 in the peripheral tissues compared to that of ^{125}I -A β 40.

¹²⁵I-PUT-A β 40 metabolism in the peripheral tissues. To investigate the contribution of peripheral tissue metabolism on the rapid elimination of ¹²⁵I-PUT-A β 40 from the systemic circulation, in vitro degradation of ¹²⁵I-PUT-A β 40 in the presence of WT mice tissue slices (liver, kidney and spleen) as well as plasma was studied. Although ¹²⁵I-PUT-A β 40 degradation in the WT plasma was slightly higher than the degradation in DMEM, not more than 10% of the initial amount of ¹²⁵I-PUT-A β 40 was degraded in 60 min (Figure 2). The degradation of ¹²⁵I-PUT-A β 40 in the presence of liver slices was similar to that of ¹²⁵I-A β 40, with substantial degradation in 60 min. The extent of ¹²⁵I-PUT-A β 40 degradation in the kidney and spleen was significantly lower compared to that of ¹²⁵I-A β 40 (Figure 2). These results demonstrate that despite rapid clearance from the peripheral circulation compared to ¹²⁵I-A β 40, the metabolism of ¹²⁵I-PUT-A β 40 in the peripheral organs of elimination was significantly lower than that of ¹²⁵I-A β 40.

¹²⁵I-A β 40 Brain Uptake. It has been established in our earlier studies that the PS value, which is a measure of BBB permeability of a protein, of ¹²⁵I-PUT-A β 40 is significantly higher than that of ¹²⁵I-A β 40 in APP,PS1 mice (Wengenack et al., 2000a). These transgenic mice develop distinct plaques at the age of 3 months with substantial amyloid burden by 6 months, mostly in the cortex and hippocampus (Wengenack et al., 2000) and carry significantly higher levels of A β 40 (13.9 pmol/ml) in the peripheral circulation compared to WT mice (2.9 pmol/ml) at 6 months (Poduslo et al., 2001). It was shown that the plaque burden in APP,PS1 animals increases linearly with age (Wengenack et al., 2000b), and the endogenous A β 40 levels in the peripheral circulation are expected to follow a similar trend. The efficacy of PUT-A β 40 to target

plaques in older APP,PS1 animals with high endogenous levels of A β 40 may be compromised if A β 40 competes with PUT-A β 40 for the BBB uptake. Hence it is important to determine if A β 40 can competitively inhibit the PUT-A β 40 absorption at the BBB. It was observed that when 1 mg of A β 40 was co-administered with 100 μ Ci of 125 I-PUT-A β 40, the PS values of 125 I-PUT-A β 40 decreased significantly in various brain regions (Figure 3). The V_p values, however, did not change significantly due to the co-administration of unlabeled A β 40 (Figure 3). To verify that the reduction in the PS values was not due to change in the pharmacokinetics of 125 I-PUT-A β 40 resulting from a possible interaction with unlabeled A β 40 in the syringe prior to injection, the PS values were determined by first injecting 1 mg of unlabeled A β 40 immediately followed by 100 μ Ci of 125 I-PUT-A β 40. The PS values of 125 I-PUT-A β 40 obtained from this experiment were not significantly different from the PS values obtained when 125 I-PUT-A β 40 was co-administered with A β 40 (data not shown). These results demonstrate that the endogenous A β 40 levels in the peripheral circulation can reduce the permeability of 125 I-PUT-A β 40 as well as 125 I-A β 40 (Kandimalla et al., 2005) at the BBB.

Brain slice uptake studies. After permeating the BBB, 125 I-A β 40 or 125 I-PUT-A β 40 must diffuse across the brain parenchyma to reach the plaque sites. The relative diffusivities of 125 I-A β 40 and 125 I-PUT-A β 40 across the brain parenchyma may be directly related to their plaque targeting capabilities. Hence the uptake of 125 I-A β 40 and 125 I-PUT-A β 40 into WT mouse brain slices was determined in vitro.

Effect of time. The uptake of ^{125}I -A β 40 into WT mouse brain slices was linear till 15 min and reached a plateau from 15 to 60 min (Figure 4).

Effect of donor concentration. Uptake of ^{125}I -A β 40 across the WT mouse brain slices was non-linearly dependent upon the donor concentration (Figure 5). Upon fitting a Michaelis-Menten type expression to the data, the K_m and V_{max} were estimated to be 18.4 $\mu\text{Ci/ml}$ and 2622 nCi/g wet weight, respectively, whereas 24.8 nCi/g wet weight was estimated to be non-specifically bound to the tissue.

Localization of Fluorescein labeled A β 40 (F-A β 40) and PUT- A β 40 (F-PUT-A β 40) in the brain parenchyma. A laser confocal micrograph of WT brain slice incubated with F-A β 40 demonstrated intense fluorescence accumulated in the cells, most likely neurons, of cortex with faint background fluorescence (Figure 6). Laser confocal micrograph of F-PUT-A β 40 demonstrated numerous dark spots amidst intensely fluorescent background in the cortex. These results suggest that F-PUT-A β 40 was not taken up by the cells and remained in the extracellular space of the brain parenchyma (Figure 6).

Effects of metabolic inhibitors. The uptake of ^{125}I -A β 40 in the WT brain slices treated with metabolic inhibitors such as ouabain (ATPase inhibitor) or 2,4-DNP (uncoupler of oxidative phosphorylation) was reduced significantly compared to the untreated brain slices (Figure 7), suggesting that the brain slice uptake of ^{125}I -A β 40 is energy dependent and carrier mediated. The uptake of ^{125}I -PUT-A β 40 in the WT brain slices was not significantly affected in the presence of a metabolic inhibitor such as 2,4-DNP (Figure

7). Hence the uptake of ^{125}I -PUT-A β 40 in the brain slices is more likely by passive diffusion.

^{125}I -A β 40 and ^{125}I -PUT-A β 40 efflux from brain slices.

As indicated above and from earlier studies conducted in our lab, A β 40 efflux from WT brain slices could be inhibited by 2,4-DNP, which strongly suggested that it is a carrier mediated process (Kandimalla et al., 2005). In the next experiment, we evaluated the saturability of ^{125}I -A β 40 efflux process and compared it with that of ^{125}I -PUT-A β 40 (Figure 8). The initial rates of ^{125}I -A β 40 efflux from WT brain slices, normalized with the donor concentration, decreased with an increase in log donor concentration. In contrast, the normalized initial rates of ^{125}I -PUT-A β 40 efflux from WT brain slices did not change appreciably with log donor concentration. These results demonstrated that the efflux of ^{125}I -A β 40 from WT brain slices is carrier mediated, whereas the efflux of ^{125}I -PUT-A β 40 is predominantly by passive diffusion.

Biophysical characterization of A β 40 and PUT-A β 40

Circular Dichroism (CD) spectra: The CD spectra of A β 40 and PUT-A β 40 illustrated in Figure 9 demonstrate that A β 40 has a random coil structure, whereas PUT-A β 40 assumes a β -sheet structure in phosphate buffered saline (pH = 7.2) at 4°C .

Kinetics of fibril formation: It is believed that high concentration of soluble A β accumulates over time in the brain extracellular space, polymerizes into insoluble fibrils, and eventually forms amyloid plaques. The ease with which a molecule can form fibrils

is considered a direct measure of its likelihood to provide a seed for plaque formation. The ideal diagnostic probe would not form fibrils after reaching the brain parenchyma, but only bind to pre-existing plaques. We studied the fibril formation of A β 40 and PUT-A β 40 using Thioflavin-T (THT) assay (Levine, 1993). THT binds to the β -sheet structure of fibrils and emits fluorescence. The intensity of the fluorescence provides a direct measure of the extent of fibril formation. The intensity of THT fluorescence plotted against time in Figure 10 describes the kinetics of A β 40 and PUT-A β 40 fibril formation. A β 40 forms fibrils with a lag time of 2 hrs, whereas PUT-A β 40 forms fibrils readily. Moreover, the extent of fibril formation with PUT-A β 40 was substantially higher than A β 40 reflected in the larger fluorescence intensity. At the end of the experiment, the fibril formation was verified by electron microscopy (data not shown).

DISCUSSION

¹²⁵I-A β 40 and ¹²⁵I-PUT-A β 40 have demonstrated a differential ability to target amyloid plaques in APP,PS1 transgenic mice after intravenous injection. As a result, they are utilized in this study as model compounds to investigate various physiological factors (plasma clearance, BBB permeability, parenchymal diffusion and metabolism, and efflux from the CNS) and biophysical factors (effect of charge, ability to form fibrils, and affinity to plaques) that affect plaque targeting.

It is generally believed that lower plasma clearance resulting in high sustained plasma levels of the probe will enhance its BBB permeability. Our earlier studies demonstrated that ¹²⁵I-A β 40 is rapidly eliminated from the systemic circulation due to significant renal

clearance and hepatic metabolism (Kandimalla et al., 2005). Despite better plaque targeting ability, ^{125}I -PUT-A β 40 is more rapidly cleared from the systemic circulation than ^{125}I -A β 40 following IV administration. Unlike ^{125}I -A β 40, the rapid clearance of ^{125}I -PUT-A β 40 did not correlate with its metabolism in the peripheral tissues such as liver, kidney and spleen. While the metabolism of ^{125}I -PUT-A β 40 in the liver slices was only slightly lower compared to ^{125}I -A β 40, its metabolism in kidney slices was significantly lower than ^{125}I -A β 40. Since the molecular size of ^{125}I -PUT-A β 40 or ^{125}I -A β 40 is small, these molecules can be eliminated by the kidney without the need for initial catabolism in the liver. Moreover, the microvascular permeability of cationized proteins like ^{125}I -PUT-A β 40 was found to be substantially higher than the native proteins (Dellian et al., 2000), resulting in their increased renal clearance. Although, higher microvascular permeability can increase the distribution of ^{125}I -PUT-A β 40 to brain (Poduslo 1996b), increase in the renal clearance and rapid distribution to peripheral tissues could diminish the net effect. Hence, it is unlikely that the better plaque targeting ability of ^{125}I -PUT-A β 40 compared to ^{125}I -A β 40 is due to favorable plasma pharmacokinetics.

Like the BBB permeability of ^{125}I -A β 40, which decreased significantly in the presence of unlabeled A β 40 (0.125 mg–2 mg) in a dose dependent manner (Kandimalla et al., 2005), the BBB permeability of ^{125}I -PUT-A β 40 decreased when co-administered with 1 mg of A β 40. Even though the PS value of ^{125}I -PUT-A β 40 is higher than that of ^{125}I -A β 40 in WT mice, the PS value of ^{125}I -PUT-A β 40 co-administered with 1 mg of A β 40 was similar to the PS value of ^{125}I -A β 40 co-administered with 1 mg of A β 40. These results indicate

that the BBB permeability of ^{125}I -PUT-A β 40 is also saturable. Therefore, endogenous A β 40 levels in the peripheral circulation of APP,PS1 animals, which were reported to increase linearly with age, could affect the BBB permeability of ^{125}I -PUT-A β 40 to a similar extent as ^{125}I -A β 40. Based on this information it is likely that a modest 1.5–2.0 fold higher PS value of ^{125}I -PUT-A β 40 compared to ^{125}I -A β 40 (Wengenack et al., 2000a) may, at the best, have a limited contribution to the differences in their plaque targeting abilities.

Our earlier work demonstrated that the accumulation of ^{125}I -A β 40 in the extracellular space of APP,PS1 mouse brain is primarily influenced by the reduced clearance of A β 40, mediated by metabolism and/or efflux, from the brain parenchyma (Kandimalla et al., 2005). Mouse brain slices containing cortex and hippocampus were used in this study as in vitro model to investigate the role of parenchymal metabolism and uptake on the differential plaque targeting ability of ^{125}I -A β 40 and ^{125}I -PUT-A β 40. This in vitro model has been used by several researchers to study the metabolism (Newman et al., 1990) and diffusion of ions (Newman et al., 1995), small (Gredell et al., 2004) and large molecules (Patlak et al., 1998) in the brain parenchyma. Uptake of ^{125}I -A β 40 into WT mouse brain slices followed Michaelis-Menten kinetics, which suggested that the uptake is saturable. The inhibition of ^{125}I -A β 40 uptake in WT mouse brain slices by metabolic inhibitors such as 2,4DNP and ouabain suggested that it is energy dependent and most likely carrier mediated. Preferential localization of F-A β 40 in the brain parenchymal cells, most likely neurons, following a short incubation time (5 min) further confirms the presence of carrier mediated transport of A β 40.

In contrast, the metabolic inhibitors such as 2,4DNP did not affect the uptake of ^{125}I -PUT-A β 40 significantly, thereby, suggesting that the uptake of ^{125}I -PUT-A β 40 in WT mouse brain slices is most likely by passive diffusion. Localization of F-PUT-A β 40 in the extracellular space of the brain parenchyma but not in the cells provides further evidence that there is no receptor mediated uptake of PUT-A β 40. The cellular uptake of A β 40 in the brain parenchyma makes it unavailable for targeting the plaques located in the extracellular space. In contrast, PUT-A β 40 is not taken up by the cells, remains in the extracellular space, and is available for binding to plaques, a desirable feature for imaging amyloid plaques.

In vitro fibril binding studies demonstrated that both ^{125}I -A β 40 and ^{125}I -PUT-A β 40 bind to A β 40 fibrils with similar affinity (data not shown). However, the differences in the extracellular concentrations of the probe can alter plaque binding significantly. The extracellular concentration of ^{125}I -A β 40 is not only reduced due to cellular uptake but also by the efflux and parenchymal metabolism. The degradation of ^{125}I -PUT-A β 40 in the WT mouse brain slices was significantly lower than the previously reported degradation of ^{125}I -A β 40 (Kandimalla et al., 2005). The efflux of ^{125}I -A β 40 across WT mouse brain slices was found to be saturable and inhibited by 2,4-DNP (Kandimalla et al., 2005), thereby, suggesting that it is energy dependent and carrier mediated. The efflux of ^{125}I -PUT-A β 40 on the other hand was much slower compared to that of ^{125}I -A β 40 and was not dependent upon the donor concentration suggesting that it occurs via passive diffusion.

Despite its success in providing contrast enhancement of plaques following IV injection during MRI of APP, PS1 mouse brains *ex vivo*, the utility of PUT-Gd-A β 40 for diagnostic use in animal models and patients is limited because:

- a) carbodiimide-mediated modification of A β 40 with putrescine is associated with problems inherent with the protein itself, such as crosslinking, aggregate and/or fibril formation, and insolubility.
- b) PUT-A β 40 forms fibrils more readily than A β 40. The ease with which a molecule can form fibrils is considered as a direct measure of its likelihood to provide a seed for plaque formation.

Hence a new probe, Gd[N-4ab/Q-4ab]A β 30, was produced as a putative MRI contrast enhancement agent by first synthesizing a glutamyl-4-aminobutane or asparagyl-4-aminobutane, which were then incorporated into the synthesis of the protein using standard solid phase methods (Poduslo et al., 2004). The complete chemical synthesis of this probe eliminates peptide crosslinking, aggregate and fibril formation, and insolubility that affected the carbodiimide-mediated modification of A β 40 with putrescine. Apart from having the chemical purity, this probe is devoid of the neurotoxic domain found in A β 40 and is not amyloidogenic like A β 40. Additionally, Gd[N-4ab/Q-4ab]A β 30 has good BBB permeability and labels neuritic plaques *in vitro* with affinity comparable to PUT-A β 40. However, attempts to image amyloid plaques in APP,PS1 animals *in vivo* using this agent yielded only modest results. Studies are being conducted to enhance the *in vivo* efficacy of this probe through appropriate structural modifications to influence various physiological factors, parenchymal metabolism and

neuronal uptake, that were determined in the present study to adversely affect the plaque targeting ability.

In summary, these studies demonstrated that both ^{125}I -A β 40 and ^{125}I -PUT-A β 40 are rapidly eliminated from the systemic circulation following IV administration in WT animals. However, the peripheral pharmacokinetics of the probes did not significantly influence their plaque targeting capabilities. The higher concentration of endogenous A β 40 in the peripheral circulation decreases the permeability of both compounds at the BBB. The metabolism of ^{125}I -PUT-A β 40 is substantially lower in the brain slices compared to that of ^{125}I -A β 40. This indicates that ^{125}I -PUT-A β 40 is metabolically stable and may remain intact in the brain parenchyma with higher concentrations being available for plaque targeting than ^{125}I -A β 40. Also, the rate of ^{125}I -PUT-A β 40 efflux in WT brain slices was substantially lower compared to that of ^{125}I -A β 40. Hence ^{125}I -PUT-A β 40 tends to remain in brain parenchyma longer than ^{125}I -A β 40. This study also demonstrates that the fluoresceine labeled A β 40, but not ^{125}I -PUT-A β 40, is taken up by cells, which makes the former unavailable for targeting the plaques located in the extracellular space. By comparing the distribution and metabolism of ^{125}I -A β 40 and ^{125}I -PUT-A β 40 following IV administration, it can be concluded that the inadequate targeting of ^{125}I -A β 40 to amyloid plaques despite its carrier mediated uptake at the BBB could be due to cellular uptake, metabolism, and efflux of A β 40 in the brain parenchyma. The knowledge gained from these studies will be very useful in the development of new A β derivatives with improved BBB permeability and plaque targeting.

ACKNOWLEDGEMENTS

We thank Dr. Dan McCormick and Jane A. Petersen for extending their technical expertise in synthesizing A β 40; Dr. Karen Duff for the PS1 transgenic mouse line; Dawn Gregor for her excellent technical assistance; and Jennifer Scott for her excellent secretarial assistance.

REFERENCES

- Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC and Barrio JR (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. *J. Neurosci. Methods* **21**:RC189.
- Bacsikai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D and Hyman BT (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. *Nat. Neurosci.* **7**:369-372.
- Dellian M, Yuan F, Trubetskoy VS, Torchilin VP and Jain RK (2000) Vascular permeability in a human tumour xenograft: molecular charge dependence. *Br. J. Cancer* **82**:1513-1518.
- Gredell JA, Turnquist PA, Maciver MB and Pearce RA (2004) Determination of diffusion and partition coefficients of propofol in rat brain tissue: implications for studies of drug action in vitro. *Br. J. Anaesth.* **93**:810-817.
- Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM and Poduslo JF (2005) Pharmacokinetic Analysis of the Blood-Brain Barrier Transport of ^{125}I -A β 40 in Wild Type and Alzheimer's Disease Transgenic Mice (APP, PS1) and Its Implication for Amyloid Plaque Formation. *J. Pharmacol. Exp. Ther.*
- Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA and Langstrom B

- (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol* **55**:306-319.
- Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B and Zlokovic BV (2002) Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. *Vas. Pharmacol.* **38**:303-313.
- Maness LM, Banks WA, Podlisny MB, Selkoe DJ and Kastin AJ (1994) Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier. *Life Sci.* **55**:1643-1650.
- Newman GC, Hospod FE and Patlak CS (1990) Kinetic model of 2-deoxyglucose metabolism using brain slices. *J. Chem. Doc.* **10**:510-526.
- Newman GC, Hospod FE, Qi H, Patel H, Trowbridge SD and Patlak CS (1995) Effects of K⁺, pH and glutamate on 45Ca kinetics in hippocampal brain slices. *J. Neurosci. Nurs.* **59**:111-120.
- Patlak CS, Hospod FE, Trowbridge SD and Newman GC (1998) Diffusion of Radiotracers in Normal and Ischemic Brain Slices. **18**:776-802.
- Poduslo JF and Curran GL (1996a) Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine. *J. Neurochem.* **67**:734-741.
- Poduslo JF and Curran GL (1996b) Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. *J. Neurochem.* **66**:1599-1609.

- Poduslo JF, Curran GL, Haggard JJ, Biere AL and Selkoe DJ (1997) Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier.[see comment]. *Neurobiol. Dis.* **4**:27-34.
- Poduslo JF, Curran GL, Peterson JA, McCormick DJ, Fauq AH, Khan MA and Wengenack TM (2004) Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. *Biochemistry* **43**:6064-6075.
- Poduslo JF, Curran GL, Sanyal B and Selkoe DJ (1999) Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. *Neurobiol. Dis.* **6**:190-199.
- Poduslo JF, Curran GL, Wengenack TM, Malester B and Duff K (2001) Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. *Neurobiol. Dis.* **8**:555-567.
- Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ and Jack CR, Jr. (2002) Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. *Neurobiol. Dis.* **11**:315-329.
- Skovronsky DM, Zhang B, Kung MP, Kung HF, Trojanowski JQ and Lee VM (2000) In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. *Proc. Natl. Acad. Sci. U.S.A.* **97**:7609-7614.
- Wengenack TM, Curran GL and Poduslo JF (2000a) Targeting alzheimer amyloid plaques in vivo. *Nat. Biotechnol* **18**:868-872.

Wengenack TM, Whelan S, Curran GL, Duff KE and Poduslo JF (2000b) Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. *Neuroscience* **101**:939-944.

Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH and Frangione B (1993) Blood-brain barrier transport of circulating Alzheimer's amyloid beta. *Biochem. Biophys. Res. Commun.* **197**:1034-1040.

FOOTNOTES

*Present address: College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307

Supported by NIH R01 AG22034 and NIH/NCRR/RCMI G12RR03020

FIGURE LEGENDS

Figure 1. Plasma pharmacokinetics of ^{125}I -A β 40[‡] (n=12) and ^{125}I -PUT-A β 40 in 24 week old WT mice (n=3). Data are mean \pm S.D; lines indicate the fit of the two-compartment pharmacokinetic model to the plasma concentration-time data; [‡]from Kandimalla et al., 2005.

Figure 2. Degradation of ^{125}I -A β 40[‡] and ^{125}I -PUT-A β 40 in various tissues obtained from 24 week old WT mice. Data are mean \pm S.D. (n = 5); [‡]from Kandimalla et al., 2005.

Figure 3. Effect of 1 mg (231 nM) of unlabeled A β 40 co-administered intravenously with ^{125}I -PUT-A β 40 (100 μCi) on the permeability surface area product (PS) and brain vascular volume (V_p) of ^{125}I -PUT-A β 40 at the blood brain barrier in 24 week old WT mice. Each result represents the mean \pm S.D. for three experiments. The differences between the PS values of control (^{125}I -PUT-A β 40) and treatment (^{125}I -PUT-A β 40 + A β 40) was determined to be statistically significant (p<0.05) by two-way ANOVA followed by Bonferroni post-tests.

Figure 4. Effect of time on the uptake of ^{125}I -A β 40 into 24 week old WT brain slices in vitro. Data are mean \pm S.D (n = 5).

Figure 5. Effect of donor concentration on the uptake of ^{125}I -A β 40 into 24 week old WT brain slices in vitro. Data are mean \pm S.D (n = 5). Curves represent predictions of Michaelis-Menten type model fitted to the data.

Figure 6. Accumulation of Fluorescein labeled A β 40 and Fluorescein labeled PUT-A β 40 in the neurons and extracellular space of WT mouse brain slices in vitro, respectively (20X).

Figure 7. Effect of metabolic inhibitors on the uptake of ^{125}I -A β 40 and ^{125}I -PUT-A β 40 in 24 week old WT brain slices in vitro. Data are mean \pm SD (n = 5); (*p<0.05, Student's t-test).

Figure 8. Effect of donor concentration on the efflux rates of ^{125}I - A β 40 and ^{125}I -PUT-A β 40 from 24 week old WT brain slices in vitro. Initial rates of efflux from the brain slices were normalized by the donor concentrations and plotted against log donor concentrations. Curve represents prediction of one-site competitive binding model using GraphPad Prism version 3.03.

Figure 9. CD spectra of ^{125}I - A β 40 and ^{125}I -PUT-A β 40 in PBS (pH = 7.2) at 4 °C

Figure 10. Kinetics of ^{125}I - A β 40 and ^{125}I -PUT-A β 40 fibril formation. THT binds to the β -sheet structure of the fibrils and emits fluorescence. The intensity of the fluorescence provides a direct measure of the extent of fibril formation.

Table 1. Comparison of the plasma pharmacokinetic parameters of ^{125}I -A β 40 and ^{125}I -PUT-A β 40 in 24 week WT mice

Parameters	^{125}I -A β 40 ¹	^{125}I -PUT-A β 40	p
C_{max} ($\mu\text{Ci/mL}$)	17.4 \pm 2.7	8.6 \pm 3.4	*
T_{1/2} (α) (min)	0.9 \pm 0.1	0.5 \pm 0.1	**
T_{1/2} (β) (min)	9.2 \pm 2.3	8.9 \pm 3.6	ns
Clearance (ml/min/g)	0.09 \pm 0.02	0.23 \pm 0.08	*
V_{ss} (ml/g)	0.9 \pm 0.17	2.2 \pm 0.7	*
AUC (min x $\mu\text{Ci/mL}$)	50.5 \pm 7.3	18.5 \pm 7.0	**

Mean \pm S.D (n=3); Statistical significance was indicated by *p<0.05 and **p<0.01 using Student's t-test; ns: non-significant p > 0.05; ¹ from Kandimalla et al., 2005

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7




Figure 8




Figure 9




Figure 10

